Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.

ABSTRACT:

Objective

To assess the clinical benefit and actionability of molecular targets for genome targeted cancer drugs recommended for clinical practice by the National Comprehensive Cancer Network (NCCN).

Design

Cross sectional study.

Participants/setting

Genome targeted cancer drugs recommended by NCCN guidelines in the advanced setting.

Main outcome measures

Molecular target actionability was assessed using the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). Clinical benefit of genome targeted oncology therapies was evaluated using the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS). Molecular targets at ESCAT category level I associated with studies showing substantial clinical benefit by ESMO-MCBS

SUBMITTER: Tibau A 

PROVIDER: S-EPMC11333991 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature